These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 28320716)

  • 1.
    Lob SH; Hackel MA; Kazmierczak KM; Young K; Motyl MR; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.
    Karlowsky JA; Lob SH; Kazmierczak KM; Hawser SP; Magnet S; Young K; Motyl MR; Sahm DF
    J Antimicrob Chemother; 2018 Jul; 73(7):1872-1879. PubMed ID: 29659861
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.
    Lob SH; Hackel MA; Kazmierczak KM; Hoban DJ; Young K; Motyl MR; Karlowsky JA; Sahm DF
    Diagn Microbiol Infect Dis; 2017 Jun; 88(2):171-176. PubMed ID: 28291628
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Sahm DF
    J Med Microbiol; 2020 Feb; 69(2):207-217. PubMed ID: 31976856
    [No Abstract]   [Full Text] [Related]  

  • 6. Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016.
    Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
    J Glob Antimicrob Resist; 2018 Dec; 15():140-147. PubMed ID: 30071354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City.
    Lapuebla A; Abdallah M; Olafisoye O; Cortes C; Urban C; Landman D; Quale J
    Antimicrob Agents Chemother; 2015 Aug; 59(8):5029-31. PubMed ID: 26014931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
    Karlowsky JA; Hoban DJ; Hackel MA; Lob SH; Sahm DF
    J Med Microbiol; 2017 Jan; 66(1):61-69. PubMed ID: 28051952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015-2017.
    Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
    J Glob Antimicrob Resist; 2020 Jun; 21():223-228. PubMed ID: 31698105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.
    Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
    Int J Antimicrob Agents; 2020 Jan; 55(1):105841. PubMed ID: 31704217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Activity of Imipenem/Relebactam Against Gram-Negative Bacilli from Pediatric Patients-Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program 2015-2017.
    Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
    J Pediatric Infect Dis Soc; 2021 Apr; 10(3):274-281. PubMed ID: 32535630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.
    Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Gueny ME; Sahm DF
    J Antimicrob Chemother; 2019 Aug; 74(8):2284-2288. PubMed ID: 31086960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017.
    Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
    Diagn Microbiol Infect Dis; 2019 Oct; 95(2):212-215. PubMed ID: 31174995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
    Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016.
    Lob SH; Hoban DJ; Young K; Motyl MR; Sahm DF
    J Glob Antimicrob Resist; 2018 Dec; 15():12-19. PubMed ID: 29857057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center.
    Kulengowski B; Burgess DS
    Pathog Dis; 2019 Jun; 77(4):. PubMed ID: 31365075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa.
    Delgado-Valverde M; Portillo-Calderón I; Alcalde-Rico M; Conejo MC; Hidalgo C; Del Toro Esperón C; Pascual Á
    Eur J Clin Microbiol Infect Dis; 2024 Mar; 43(3):445-457. PubMed ID: 38157139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019.
    Jean SS; Lu MC; Ho MW; Ko WC; Hsueh PR;
    Int J Antimicrob Agents; 2022 Mar; 59(3):106521. PubMed ID: 35066144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Porins and bla
    Balabanian G; Rose M; Manning N; Landman D; Quale J
    Microb Drug Resist; 2018 Sep; 24(7):877-881. PubMed ID: 29782237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.